KIT and ischemic cardiomyopathy: However, current cell therapy with adult c-kit+ CPCs for ischemic cardiomyopathy is largely limited by the poor survival and retention of transplanted stem cells [13, 14] and also by the lack of robust de novo differentiation of transplanted stem cells into mature cardiac cell types [14, 15].